By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Select Your Cherished Fish - 2Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- 3From Dread to Certainty: Individual Accounts of Strengthening
- 4Reclassifying Achievement: Individual Accounts of Seeking after Interests
- 5Defeating An inability to embrace success in Scholarly world: Individual Victories
- Chevron Says Damage at Wheatstone LNG Will Hamper Restart
- Geomagnetic storm grounds launch of Mars space weather satellites
- Massive supernova explosion may have created a binary black hole
- Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo.
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- Share your pick for the tree that you love for its novel magnificence!
- UK consumer confidence plunges amid escalating Iran conflict
